Amylyx reported a Q4 net loss of USD 33.0 million and a FY net loss of USD 144.7 million. Q4 R&D expenses were USD 21.2 million and Q4 SG&A expenses were USD 15.4 million, while FY R&D expenses were USD 90.4 million and FY SG&A expenses were USD 62.9 million. Cash, cash equivalents and short-term investments totaled USD 317.0 million at December 31, 2025, and the company said its cash runway is expected to extend into 2028. On the business side, Amylyx said recruitment is complete for its pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia $(PBH)$, with topline data expected in Q3 2026 and, if approved, a commercial launch in 2027. The company also announced AMX0318, a novel GLP-1 receptor antagonist designed for long-acting administration, as a development candidate for PBH and other rare diseases, with IND-enabling studies underway and an IND filing targeted for 2027. In addition, Amylyx presented early Phase 1 LUMINA safety and tolerability data for AMX0114 in ALS and expects completion of enrollment for Cohort 2 in March 2026, with Cohort 1 biomarker data expected in H1 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260303771323) on March 03, 2026, and is solely responsible for the information contained therein.
Comments